On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression
The data may be early and the patient population small, but in biotech today, who’s waiting for complete clarity?
On the day after the FDA blessed Sage Therapeutics $SAGE with its inside track on their oral depression drug SAGE-217, Japan’s Shionogi has stepped in with a $575 million deal to gather up limited Asian rights to the drug — with $90 million coming in as cash upfront.
Sage is on a roll, and they know it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.